See more : Orora Limited (ORA.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Precision BioSciences, Inc. (DTIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precision BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Banyan Acquisition Corporation (BYN-UN) Income Statement Analysis – Financial Results
- Ghida Alsultan for Fast Food Co. (9567.SR) Income Statement Analysis – Financial Results
- E.ON SE (EOAN.SW) Income Statement Analysis – Financial Results
- Energy International Investments Holdings Limited (0353.HK) Income Statement Analysis – Financial Results
- Gruppo MutuiOnline S.p.A (0O2B.L) Income Statement Analysis – Financial Results
Precision BioSciences, Inc. (DTIL)
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 48.73M | 25.10M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
Cost of Revenue | 8.26M | 9.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 40.47M | 16.09M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
Gross Profit Ratio | 83.06% | 64.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 53.38M | 83.94M | 115.24M | 98.06M | 82.42M | 45.12M | 20.32M | 9.10M |
General & Administrative | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 6.10M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -9.76M | 0.00 | 0.00 | 0.00 |
Operating Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.20M |
Cost & Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.84M |
Interest Income | 7.69M | 3.47M | 208.00K | 822.00K | 4.27M | 1.88M | 872.00K | 570.00K |
Interest Expense | 2.23M | 1.11M | 132.00K | 0.00 | 182.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 8.26M | 9.00M | 10.20M | 9.81M | 5.32M | 2.35M | 1.44M | 640.00K |
EBITDA | -32.04M | -62.79M | -20.27M | -99.19M | -87.38M | -43.68M | -20.42M | -8.19M |
EBITDA Ratio | -65.76% | -392.35% | -24.94% | -408.45% | -392.92% | -418.62% | -313.12% | -116.72% |
Operating Income | -43.74M | -100.37M | -39.40M | -109.83M | -87.20M | -47.91M | -21.97M | -8.83M |
Operating Income Ratio | -89.76% | -399.90% | -34.11% | -452.25% | -392.14% | -440.25% | -338.90% | -125.84% |
Total Other Income/Expenses | 1.21M | 27.46M | 8.80M | 822.00K | -5.67M | 1.88M | 872.00K | 572.00K |
Income Before Tax | -42.53M | -111.64M | -30.60M | -109.01M | -92.88M | -46.04M | -21.10M | -8.26M |
Income Before Tax Ratio | -87.28% | -444.80% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.69% |
Income Tax Expense | 0.00 | 11.27M | 316.00K | 10.43M | -9.58M | 1.88M | -754.00K | -5.00K |
Net Income | -61.32M | -122.91M | -30.92M | -109.01M | -83.30M | -46.04M | -21.10M | -8.25M |
Net Income Ratio | -125.84% | -489.71% | -26.76% | -448.86% | -374.59% | -423.02% | -325.45% | -117.62% |
EPS | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
EPS Diluted | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
Weighted Avg Shares Out | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Weighted Avg Shares Out (Dil) | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Precision BioSciences to Report Second Quarter Results on August 4, 2023
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
Precision Biosciences: Plenty Of Positive Updates; Waiting For The Market To Notice
3 Penny Stocks to Catapult You Into the Millionaires' Club
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
Precision BioSciences to Present at Upcoming June Investor Conferences
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
Source: https://incomestatements.info
Category: Stock Reports